Search Results

Nectero Medical today announced the closing of its $96 million Series D financing round.

According to Vision Research Reports, the U.S. biotechnology market size was valued at USD 552.43 billion in 2023 and is anticipated to hit around USD 1,785.96 billion by 2033, growing at a CAGR of 12.45% from 2024

Akero Therapeutics, Inc. released preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis, fibrosis stage 2 or 3.

Venatorx Pharmaceuticals and Menarini Group today announced that they have entered into an agreement under which Menarini will acquire the exclusive rights to commercialize, upon approval of relevant health authorities, cefepime-taniborbactam in 96 countries.

Akero Therapeutics, Inc will hold an investor conference on Monday, March 4 at 8:00 a.m. ET to share results after 96 weeks of treatment for its HARMONY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3).

QIAGEN announced the U.S. Food and Drug Administration clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the United States.

PacBio today announced two new high throughput library preparation kits and workflows optimized for its Revio sequencing system.

World Precision Instruments is excited to expand the capability of the EVOM™ Auto, now offering both 24 and 96 multiwell capacity in one single platform.

IceCure Medical Ltd. announced today that it has submitted final data to the U.S. Food and Drug Administration (“FDA”) requesting marketing authorization for ProSense® for the indication of treating patients with early stage T1 invasive breast cancer with cryoablation and adjuvant hormone therapy.